Respiratory Pipeline, New Launches could Work Well for Cipla

What happened

Cipla's September-quarter earnings fell year on year because of a high base in its US business and weak sales of active pharmaceutical ingredients, which are the raw drug ingredients it sells. Revenue and net profit still rose from the previous quarter on India growth and respiratory products.

Confirmed

Global impact / market context

Cipla is shifting its US business toward respiratory medicines, including a newly approved generic dry-powder inhaler, a device that delivers drug powder into the lungs. If these launches sell well, they can replace revenue lost as older products normalized and support profit per sale.

Analyst inference

Investors are weighing a weak year-on-year quarter against sequential improvement and a promised second-half recovery. The stock's path likely depends on whether India's double-digit growth and US respiratory launches deliver cash available to fund new products and defend market share.

Analyst inference

What to watch

1. Cipla received approval for generic Advair, its first dry-powder inhaler approved from its US manufacturing network, and expects contributions from additional respiratory and peptide products over coming quarters. Confirmed
2. Watch whether the US respiratory launches actually convert into sales growth, since the article gives no launch revenue figures and the recovery depends on these products gaining prescriptions. Analyst inference
3. Track India business growth and the share of chronic therapies, because Cipla expects these to sustain domestic market share gains and offset weakness in active pharmaceutical ingredient sales. Analyst inference

Evidence

• Original source link unavailable